#### REMARKS

In response to the Restriction Requirement dated April 17, 2006, Applicants elect the invention of Group I, claims 1, 3, and 13-16, drawn to a method of inhibiting osteoclast-mediated bone resorption comprising inhibiting activity of a gene product encoded by an osteoclast-associated gene, and Applicants further elect the osteoclast-associated gene/marker of OC14, disclosed in Figure 1A, without traverse.

Upon entry of the present amendment, claims 1 and 25-33 are pending. Claims 2-24 have been cancelled without prejudice or disclaimer. Applicants reserve the right to prosecute the cancelled subject matter, as well as the originally presented claims, in continuing applications. Claim 1 has been amended and claims 25-33 have been added. Support for the amendments presented herein is found throughout the specification and claims as originally filed. For example, support for the amendments to claim 1 is found at least in Figure 1A, and in publicly available Genbank Accession No. AV251613, which is referred to by name in line 14 of Figure 1A: "C80638 (AV251613 RIKEN full-length enriched, 0 day neonate head Mus musculus cDNA clone 4833432F11 3', mRNA sequence)". A copy of the NCBI Entrez Database Entry for AV251613 is enclosed herewith for the Examiner's convenience. The nucleotide sequence of OC14 (AV251613) has been assigned the next available sequence identifier, *i.e.*, SEQ ID NO:50. Support for new claims 25-26 is found at least in the first paragraph on page 49 of the as-filed specification, while support for new claims 27-33 is found at least in the second paragraph on page 49 of the as-filed specification. Accordingly, no new matter has been added by the claim amendments presented herein.

### **CONCLUSION**

On the basis of the foregoing amendment and remarks, Applicants respectfully submit, that the pending claims are in condition for allowance. If there are any questions regarding this amendment and/or these remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

Ingrid A. Beattie, Reg. No. 42,306


Attorney for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY & POPEO, P.C.

Tel.: (617) 542 6000 Fax: (617) 542-2241 Customer No. 30623

TRA 2187487v.1



sequencing pipeline with 384 multicapillary sequencer. Genome Res.. 10 (11), 1757-1771 (2000) Konno, H., Fukunishi, Y., Shibata, K., Itoh, M., Carninci, P., Sugahara

RIKEN integrated sequence analysis (RISA) system -- 384 - format

,Y. and Hayashizaki,Y.

Computer-based methods for the mouse full-length cDNA encyclopedia: real-time sequence clustering for construction of a nonredundant cDNA library. Genome Res.. 11 (2), 281-289 (2001) Kondo, S., Shinagawa, A., Saito, T., Kiyosawa, H., Yamanaka, I., Aizawa ,K., Fukuda,S., Hara,A., Itoh,M., Kawai,J., Shibata,K. and

Hayashizaki, Y.

```
Hayashizaki, Y.
```

Computational Analysis of Full-Length Mouse cDNAs Compared with Human Genome Sequences Mamm. Genome. 12, 673-677 (2001)

Please visit our web site (<a href="http://genome.gsc.riken.go.jp/">http://genome.gsc.riken.go.jp/</a>) for further details.

cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues.

# FEATURES source

Location/Qualifiers
1..668
/organism="Mus musculus"
/mol\_type="mRNA"
/strain="C57BL/6J"
/db\_xref="taxon:10090"
/clone="4833432F11"
/sex="mixed"
/tissue\_type="head"
/dev stage="0 day neonate"

/lab\_host="DH10B"

/clone\_lib="RIKEN full-length enriched, 0 day neonate head"

/note="Site\_1: SalI; Site\_2: BamHI; cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues. 1st strand cDNA was primed with a primer [5'

## ORIGIN

//

```
tggagcagag gtttccattg tgtctctcag agcagaaacg gttggcctnt gtgttgcaac ctcagcatc gcagtgcta tacgaattct gactacattc ctgatggtgt gtttcgctgg ctttaacata aaggaaaaga tatttattc ttttgcctgg cttccaaagg ccacggtcca ggctgcatt ggctctgtgg ctctggacac ggcaagatcc cacggagaga agcagctgga 241 agactatggg atggatgtgc tgacggtggc atttttggcc atcctcatta cagcaccaat 301 tggaagccta ctgattggtt tgctgggtcc cagggttctt cagaaaatctg aacatcgaac 361 cgaagaggag gttcaaggag agacttctgc acacattcag aggaagcctg aggattccat 421 tacggaagcc tgatggaca tgttaccat cccaaccaa aggttttggc cctccaacaa 481 ccgggacaac tttacttccc tttgactcag aagaaaactt cccgtggaat ttcataagca 541 aacaaattag aaagctttac gctgctaaca gtacctcagg tgtttacttc ctcagaaaga 601 ccggaggaca ggttacttca gaaagtgaga gaaagtaatt tggacaaata aaacattcac 661 gattttgt
```

### <u>Disclaimer | Write to the Help Desk</u> <u>NCBI | NLM | NIH</u>

Jul 24 2006 17:22:14